Condition category
Eye Diseases
Date applied
09/05/2005
Date assigned
16/05/2005
Last edited
18/02/2008
Prospective/Retrospective
Retrospectively registered
Overall trial status
Completed
Recruitment status
No longer recruiting

Plain English Summary

Not provided at time of registration

Trial website

Contact information

Type

Scientific

Primary contact

Dr Ricardo Agurto-Rivera

ORCID ID

Contact details

Exequiel Fernández nº 920
Casa F
Ñuñoa
Santiago
Chile
+56 8 5021968
ricardo_agurto@yahoo.com

Additional identifiers

EudraCT number

ClinicalTrials.gov number

Protocol/serial number

N/A

Study information

Scientific title

Acronym

Study hypothesis

TTT plus intravitreous triamcinolone are effective treatment for choroidal neovascularization and are better than TTT alone.

Ethics approval

Not provided at time of registration

Study design

Randomised controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Trial setting

Hospitals

Trial type

Treatment

Patient information sheet

Condition

Age-Related Macular Degeneration (ARMD) not available for current therapies

Intervention

Complete ophthalmologic examination, treatment with TTT alone compared with treatment with TTT plus intravitreous Triamcinolone. Ophthalmologic control to verify closure of CNV or re-treatment.

Intervention type

Drug

Phase

Not Specified

Drug names

Triamcinolone

Primary outcome measures

Preservation of visual acuity

Secondary outcome measures

Closure of CNV, OCT characteristics

Overall trial start date

01/02/2004

Overall trial end date

28/02/2006

Reason abandoned

Eligibility

Participant inclusion criteria

Patients with severe ARMD (choroidal neovascularization [CNV]) that could not be treated with photodynamic therapy (PDT) because of bad prognosis or economical reasons.

Participant type

Patient

Age group

Not Specified

Gender

Not Specified

Target number of participants

200

Participant exclusion criteria

1. Any patient that has indication for PDT and has the economical means to get this therapy
2. Media opacity
3. Previous treatment for CNV

Recruitment start date

01/02/2004

Recruitment end date

28/02/2006

Locations

Countries of recruitment

Mexico

Trial participating centre

Exequiel Fernández nº 920
Santiago
Chile

Sponsor information

Organisation

Association to Avoid Blindness (Asociación Para Evitar La Ceguera) (APEC) (Mexico)

Sponsor details

Vicente García Torres Nº 46
Barrio San Lucas
Del Coyoacán
Mexico City
04030
Mexico
+52 10841400
retinamex@yahoo.com

Sponsor type

Not defined

Website

Funders

Funder type

Charity

Funder name

Association to Avoid Blindness (Asociación Para Evitar La Ceguera) (APEC) (Mexico)

Alternative name(s)

Funding Body Type

Funding Body Subtype

Location

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Participant level data

Not provided at time of registration

Results - basic reporting

Publication summary

2005 results on http://www.ncbi.nlm.nih.gov/pubmed/16309554

Publication citations

  1. Results

    Agurto-Rivera R, Diaz-Rubio J, Torres-Bernal L, Macky TA, Colina-Luquez J, Papa-Oliva G, Jager RD, Martinez-Jardon S, Fromow-Guerra J, Quiroz-Mercado H, Intravitreal triamcinolone with transpupillary therapy for subfoveal choroidal neovascularization in age related macular degeneration. A randomized controlled pilot study [ISRCTN74123635]., BMC Ophthalmol, 2005, 5, 27, doi: 10.1186/1471-2415-5-27.

Additional files

Editorial Notes